<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article article-type="research-article">
  <?properties open_access?>
  <!-- Original-type: ra-->
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
      <publisher>
        <publisher-name>Nature Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">10576662</article-id>
      <article-id pub-id-type="pmc">2362938</article-id>
      <article-id pub-id-type="pii">6690804</article-id>
      <article-id pub-id-type="doi">10.1038/sj.bjc.6690804</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Regular Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Sharma</surname>
            <given-names>S</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jagdev</surname>
            <given-names>S</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Coleman</surname>
            <given-names>R E</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hancock</surname>
            <given-names>B W</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lorigan</surname>
            <given-names>P C</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>YCRC Department of Clinical Oncology, Weston Park Hospital NHS Trust, Whitham Road, Sheffield S10 2SJ, UK</aff>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>1999</year>
      </pub-date>
      <volume>81</volume>
      <issue>6</issue>
      <fpage>1037</fpage>
      <lpage>1041</lpage>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>04</month>
          <year>1999</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>04</month>
          <year>1999</year>
        </date>
      </history>
      <copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement>
      <copyright-year>1999</copyright-year>
      <permissions>
        <copyright-holder>Cancer Research Campaign</copyright-holder>
      </permissions>
      <abstract>
        <p>Methotrexate (MTX) is a folate antagonist widely used both as an anticancer drug and as an immunosupressant. Administration of an 8-day methotrexate and folinic acid regime may be associated with pleuritic chest pain and pneumonitis. We have reviewed the toxicity seen in 168 consecutive patients treated with low-dose MTX for persistent trophoblastic disease. Twenty-five per cent of patients developed serosal symptoms, pleurisy was the commonest complaint. The majority of patients had mild to moderate symptoms which were controlled with simple analgesia and did not necessitate a change in treatment; 11.9% had severe symptoms which necessitated a change in treatment. One patient developed a pericardial effusion and a second patient developed severe reversible peritoneal irritation. The possible aetiology and pathophysiology of methotrexate-induced serosal toxicity is discussed. &#xA9; 1999 Cancer Research Campaign</p>
      </abstract>
      <kwd-group>
        <kwd>methotrexate</kwd>
        <kwd>pericarditis</kwd>
        <kwd>peritonitis</kwd>
        <kwd>pleurisy</kwd>
        <kwd>pneumonitis</kwd>
        <kwd>serosal complications</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>
</pmc-articleset>
